obesity

Nov 04, 2025

Intensity Therapeutics Publishes Compelling Clinical Data for INT230-6 in Advanced Cancers Intensity Therapeutics, Inc. (Nasdaq: INTS) announced the publication of its Phase 1/2 clinical results for INT230-6. The comprehensive study evaluated the intratumoral therapy's safety, efficacy, and mechanism of action a...

Oct 31, 2025

In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025,...

Sep 02, 2025

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly 360 mg subcutaneous autoinjector designed for maintenance do...

Jun 06, 2025

Over the past few years, the prevalence of chronic diseases has grown significantly, placing an increasing social and economic burden on individuals and families. Managing these long-lasting conditions requires constant attention to symptoms, medication, lifestyle changes, and emotional well-being. As a result, chr...

May 13, 2025

Eli Lilly’s ZEPBOUND Outperforms WEGOVY in SURMOUNT-5 Trial Eli Lilly and Company released detailed results from the Phase IIIb SURMOUNT-5 clinical trial, showing that ZEPBOUND (tirzepatide) significantly outperformed WEGOVY (semaglutide) in weight loss among adults with obesity or overweight and at least one we...

May 12, 2025

The pharmaceutical industry is witnessing a seismic shift, fueled by the meteoric rise of GLP-1 agonist molecules. Once a niche class of diabetes drugs, GLP-1 agonists have become the cornerstone of a global race to conquer obesity, a disease that has more than doubled in prevalence since 1990 and now affects over ...

Apr 29, 2025

Boston Scientific Pushes Forward Despite $200M Tariff Challenge Boston Scientific has announced that tariffs are expected to add approximately $200 million to its costs this year, but the company remains confident in its ability to absorb the financial hit. Despite the tariff burden, the company reported robust ...

Apr 14, 2025

The paradigm shift from Non‐alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction–associated Steatohepatitis (MASH) reflects a deeper understanding of the pathophysiology underpinning liver injury in the context of obesity, diabetes, and metabolic syndrome. This evolving nomenclature from NASH to MASH is more t...

Mar 26, 2025

Obesity is a chronic disease reaching alarming levels worldwide, leading to diabetes, cardiovascular disease, and metabolic disorders. It results from a mix of genetic, environmental, and lifestyle factors. Understanding what are the reasons for obesity—poor diet, inactivity, and hormonal imbalances—is crucial. Key...

Mar 24, 2025

Obesity has become one of the most pressing global health challenges, with its prevalence rising at an alarming rate. The causes of obesity are deeply rooted in modern lifestyles, where high-calorie diets, sedentary habits, and environmental influences create the perfect storm for excessive weight gain. Beyond life...